Olmes, Gregor Leonhard http://orcid.org/0009-0000-9334-4774
Breitbach, Georg Peter
Tepikin, Anton
Nistor, Adriana
Solomayer, Erich Franz
Hamoud, Bashar Haj
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Article History
Received: 4 June 2023
Accepted: 24 September 2023
First Online: 4 October 2023
Declarations
:
: Waiver, because the treatment of the patient followed standard of care. For this case report, the written consent to publish is available from the corresponding author on reasonable request.
: Waiver.
: Written informed consent was obtained from the patient’s family for publication of this case report after patient’s death.
: The authors declare the following conflict of interest. GL Olmes received grants from AstraZeneca (Cambridge, UK) and RG Ärztefortbildung GmbH, membership of DGGG (Berlin, Germany), AGE (Buchholz, Germany), and AGEM (Berlin, Germany). EF Solomayer is receiving grants from the University of Saarland and Storz and Erbe; personal fees and other compensation from Roche (Basel, Switzerland), Pfizer (New York City, NY, USA), Celgene (Summit USA), Amgen (Thousand Oaks, CA, USA), and AstraZeneca (Cambridge, UK); and other fees from Esai (Tokyo, Japan), Johnson & Johnson (New Brunswick, NJ, USA), Novartis (Basel, Switzerland), Tesaro (Waltham, MA, USA), Teva (Petach Tikwa, Israel), Medac GmbH (Wedel, Germany), MSD (Kenilworth, NJ, USA), Vifor (Sankt Gallen, Switzerland), Gedeon Richter (Budapest, Hungary), Takeda (Tokyo, Japan), and AGE (Buchholz, Germany); other potential conflicts are Clovis Oncology (Boulder, Colorado, USA), Genomic Health (Redwood City, California, USA), Jenapharm (Jena, Germany), Matramed (Bexbach, Germany), Mentor (Minneapolis, Minnesota, USA), Pharma Mar (Madrid, Spain), Samsung (Suwon, South Korea), University of Saarland (Saarbrücken, Germany), DGGG (Berlin, Germany), AGO (Taufkirchen, Germany), AGUB (Taufkirchen, Germany), DGS (Berlin, Germany), DKG (Berlin, Germany), Saarländisches Tumorzentrum am UKS e.V., University of Saarland (Homburg, Germany), Saarländische Krebsgesellschaft (Saarbrücken, Germany), Stiftung Endometriose Forschung (Westerstede, Germany), ESGE (Leuven, Belgium), ETC (Saarbrücken, Germany), DEGUM (Berlin, Germany), Deutsche Kontinenzgesellschaft (Frankfurt, Germany), BLFG (Berlin, Germany), Medconcept (Neustadt an der Weinstraße, Germany), Thieme (Stuttgart, Germany). B Haj Hamoud received travel grants from Gedeon Richter, AstraZeneca (Cambridge, UK), Johnson & Johnson (New Brunswick, NJ, USA), and Storz (Tuttlingen, Germany) and is member of DGGG (Berlin, Germany), AGE (Buchholz, Germany), and Stiftung Endometriose Forschung (Westerstede, Germany). GP Breitbach, A Nistor, and A Tepikin declare to have no conflict of interest.